Welcome to our dedicated page for ELUTIA SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elutia Inc. filings document the regulatory record for a medical technology company developing and commercializing drug-eluting biomatrix products. Form 8-K reports cover financial results, preliminary operating updates, Nasdaq listing notices and compliance events, and material compensation actions tied to the company's Class A common stock.
Proxy materials disclose board matters, executive compensation, equity-award information, shareholder voting items, and governance practices. The filing record also includes disclosures on inducement award plans, stock-based compensation capacity, registered securities on the Nasdaq Capital Market, and emerging growth company status.
Elutia, Inc. reported continued operating losses and significant legal and liquidity risks in its Form 10-Q. For the six months ended June 30, 2025, the company recorded a net loss of $13.5 million and an accumulated deficit of $243.1 million. Cash used in operations totaled $17.1 million year-to-date and the company expects ongoing cash outflows for the rest of 2025, raising concerns about its ability to achieve and sustain profitability.
The company completed the sale of its Orthobiologics Business (initial gain recognized of $6.0 million in 2023 and an additional $0.2 million in 2024) with potential earn-outs of up to $20 million and a $1.5 million indemnity holdback. Material litigation includes extensive FiberCel and VBM claims: the company recorded $13.3 million as a probable liability for 47 FiberCel cases and $3.7 million for VBM-related matters, with substantial settlements already paid and insurance receivables recorded. Elutia has a secured SWK loan facility with a weighted average interest rate of 12.6% for the three months ended June 30, 2025 and amended covenants requiring a minimum liquidity of $8.0 million. The company discloses substantial risks around commercialization of EluPro, supplier dependence, indemnities and contingent liabilities.
Elutia Inc. furnished an update on its business by submitting a Form 8‑K that includes a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference into this report. Elutia’s Class A common stock trades on the Nasdaq Capital Market under the symbol ELUT, and the company is identified as an emerging growth company under applicable SEC rules.
Form 4 overview: On 06/21/2025 Elutia Inc. (ELUT) filed a Form 4 detailing equity activity by President & CEO C. Randal Mills, who is also a director.
Transactions:
- 22,473 Class A shares were acquired through the vesting and settlement of an equal number of restricted stock units (RSUs) (Code “M”).
- 8,019 shares were withheld at $1.81 per share to satisfy tax obligations (Code “F”).
The net increase to the executive’s direct holdings is 14,454 shares.
Post-transaction ownership: Mills now directly owns 321,167 Class A shares. Table II shows 22,473 RSUs still outstanding, indicating additional shares may be delivered in future periods.
Award background: The underlying RSU grant was issued on 06/21/2022 for 89,893 units, vesting in four equal annual tranches beginning 06/21/2023. The current filing represents the second scheduled vesting installment.
No open-market purchases or sales occurred, and the form does not cite a Rule 10b5-1 plan. As such, the disclosure reflects a routine insider vesting event with limited immediate market impact for investors.